[go: up one dir, main page]

SG10201408500RA - Antibody producing non-human mammals - Google Patents

Antibody producing non-human mammals

Info

Publication number
SG10201408500RA
SG10201408500RA SG10201408500RA SG10201408500RA SG10201408500RA SG 10201408500R A SG10201408500R A SG 10201408500RA SG 10201408500R A SG10201408500R A SG 10201408500RA SG 10201408500R A SG10201408500R A SG 10201408500RA SG 10201408500R A SG10201408500R A SG 10201408500RA
Authority
SG
Singapore
Prior art keywords
human
nucleic acid
antibody producing
cells
producing non
Prior art date
Application number
SG10201408500RA
Inventor
Erwin Houtzager
Rui Daniel Pinto
Ton Logtenberg
Mark Throsby
Robert Arjen Kramer
Kruif Cornelis Adriaan De
Original Assignee
Merus B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41280336&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201408500R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merus B V filed Critical Merus B V
Publication of SG10201408500RA publication Critical patent/SG10201408500RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Husbandry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

94 Title: Antibody producing non-human 5 The invention provides transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to DNA rearrangements and/or somatic hypermutations. In one embodiment, the nucleic acid comprises an expression 10 cassette for the expression of a desired molecule in cells during a certain stage of development cells in developing into mature B cells. The invention further provides methods for producing an immunoglobulin from the transgenic, non-human animal. (No suitable figure)
SG10201408500RA 2008-06-27 2009-06-29 Antibody producing non-human mammals SG10201408500RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2008050430 2008-06-27

Publications (1)

Publication Number Publication Date
SG10201408500RA true SG10201408500RA (en) 2015-01-29

Family

ID=41280336

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201914019YA SG10201914019YA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914027VA SG10201914027VA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201408500RA SG10201408500RA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG10201914019YA SG10201914019YA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals
SG10201914027VA SG10201914027VA (en) 2008-06-27 2009-06-29 Antibody producing non-human mammals

Country Status (22)

Country Link
EP (6) EP2556747B1 (en)
JP (6) JP5749161B2 (en)
KR (5) KR101990228B1 (en)
CN (3) CN105191863B (en)
AU (1) AU2009263082C1 (en)
CA (1) CA2729095C (en)
CY (2) CY1114830T1 (en)
DK (3) DK2147594T3 (en)
ES (3) ES2906344T3 (en)
HR (2) HRP20220205T1 (en)
HU (1) HUE057994T2 (en)
LT (1) LT3456190T (en)
MX (1) MX2010014542A (en)
NZ (1) NZ590118A (en)
PL (2) PL3456190T3 (en)
PT (3) PT2556747T (en)
RS (2) RS62925B1 (en)
RU (2) RU2731084C2 (en)
SG (3) SG10201914019YA (en)
SI (2) SI2147594T1 (en)
WO (1) WO2009157771A2 (en)
ZA (1) ZA201009312B (en)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368733T3 (en) 2002-07-18 2011-11-21 Merus B.V. RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES.
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
GB2404382B (en) 2003-07-28 2008-01-30 Oxitec Ltd Pest control
GB2443186A (en) 2006-10-25 2008-04-30 Oxitec Ltd Expression system for mediating alternative splicing
SI2147594T1 (en) * 2008-06-27 2014-02-28 Merus B.V. Antibody producing non-human mammals
ES2908040T3 (en) 2008-09-30 2022-04-27 Ablexis Llc Mice with gene insertion for the production of chimeric antibodies
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
ES2978496T3 (en) 2009-07-08 2024-09-13 Kymab Ltd Animal models and therapeutic molecules
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
RU2724663C2 (en) 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Mouse with common light chain
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
AU2013204019B2 (en) * 2010-02-08 2014-02-27 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PL3248462T3 (en) 2010-03-31 2024-07-08 Ablexis, Llc Genetic engineering of mice for the production of chimeric antibodies
CN105695415A (en) * 2010-06-17 2016-06-22 科马布有限公司 Animal models and therapeutic molecules
CN103025884B (en) 2010-07-26 2015-11-25 特里安尼公司 Transgenic animal and using method
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
RU2612903C2 (en) * 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Mouse producing binding proteins containing vl-domains
US10130081B2 (en) 2011-08-05 2018-11-20 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
JP5813880B2 (en) * 2011-09-19 2015-11-17 カイマブ・リミテッド Antibodies, variable domains and chains made for human use
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG10201805622QA (en) 2011-12-22 2018-08-30 Hoffmann La Roche Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
US20130212719A1 (en) * 2012-02-01 2013-08-15 Regeneron Pharmaceuticals, Inc. Humanized Rodents that Express Heavy Chain Containing VL Domains
GB2500113A (en) 2012-03-05 2013-09-11 Oxitec Ltd Arthropod male germline gene expression system
MX353278B (en) * 2012-03-06 2018-01-05 Regeneron Pharma Common light chain mouse.
EP2825035A1 (en) 2012-03-16 2015-01-21 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
PT2883449T (en) 2012-03-16 2018-05-07 Regeneron Pharma Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
ES2737990T3 (en) * 2012-03-16 2020-01-17 Regeneron Pharma Rodents expressing pH sensitive immunoglobulin sequences
GB2502127A (en) * 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
PL2838917T3 (en) 2012-04-20 2019-12-31 Merus N.V. Methods and means for the production of heterodimeric Ig-like molecules
WO2013184761A1 (en) * 2012-06-05 2013-12-12 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain
JP6514103B2 (en) 2012-07-06 2019-05-15 ゲンマブ ビー．ブイ． Dimer protein with triple mutation
CN103571872B (en) * 2012-08-09 2016-11-23 山东国际生物科技园发展有限公司 A kind of preparation method of the transgenic animal that can express people's antibody
ES2692951T3 (en) 2012-09-27 2018-12-05 Merus N.V. Bispecific IgG antibodies as T cell couplers
GB201303932D0 (en) 2013-03-05 2013-04-17 Oxitec Ltd Muscle actin promoter
CN108611369B (en) * 2013-03-13 2022-08-26 瑞泽恩制药公司 Mice expressing restricted immunoglobulin light chain repertoire
MX368258B (en) 2013-03-15 2019-09-25 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same.
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
TW201546284A (en) 2013-10-01 2015-12-16 Kymab Ltd Animal model and therapeutic molecule
RS55472B1 (en) * 2013-10-15 2017-04-28 Regeneron Pharma Humanized il-15 animals
ES2916722T3 (en) 2013-12-27 2022-07-05 Zymeworks Inc Sulfonamide-containing linkage systems for drug conjugates
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
KR20160145560A (en) 2014-02-28 2016-12-20 메뤼스 엔.페. Antibody that binds erbb-2 and erbb-3
KR102276752B1 (en) 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 Non-human animals that make single domain binding proteins
US20150266976A1 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
GB2526867A (en) * 2014-06-05 2015-12-09 Oxitec Ltd Gene expression system
SG11201702143PA (en) 2014-09-17 2017-04-27 Zymeworks Inc Cytotoxic and anti-mitotic compounds, and methods of using the same
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
JP7010811B2 (en) 2015-07-10 2022-02-10 メルス ナムローゼ フェンノートシャップ Human CD3 binding antibody
CA2995717A1 (en) 2015-08-24 2017-03-02 Trianni, Inc. Enhanced production of immunoglobulins
KR20180100305A (en) 2015-10-23 2018-09-10 메뤼스 엔.페. Binding molecules that inhibit cancer growth
WO2017095939A1 (en) 2015-12-03 2017-06-08 Trianni, Inc. Enhanced immunoglobulin diversity
US11053288B2 (en) 2016-02-04 2021-07-06 Trianni, Inc. Enhanced production of immunoglobulins
HRP20250471T1 (en) 2016-06-03 2025-06-06 Regeneron Pharmaceuticals, Inc. RODENTS EXPRESSING EXOGENEOUS TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE
BR112019002771A2 (en) 2016-08-12 2019-05-14 Oxitec Ltd doublesex union control module polynucleotide, gene expression system, expression vector plasmid, genetically engineered insect, methods for producing genetically engineered insects, for selectively cultivating genetically engineered male insects, for reducing a wild insect population, for breeding a transgenic aedes aegypti mosquito and to detect the presence of a dna molecule, chromosomal target site of aedes aegypti, genetically engineered aedes aegypti mosquito, dna molecule, and dna detection kit.
EP4342912A3 (en) 2016-09-23 2024-05-22 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
CA3094322A1 (en) * 2017-03-20 2018-09-27 Washington University Cells and methods of uses and making the same
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
CA3058342A1 (en) 2017-03-31 2018-10-04 Merus N.V. Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour
US12195551B2 (en) 2017-05-17 2025-01-14 Merus N.V. Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer
EP3649155A1 (en) 2017-07-06 2020-05-13 Merus N.V. Bispecific anti pd1-anti tim3 antibodies
EP3649156A1 (en) 2017-07-06 2020-05-13 Merus N.V. Antibodies that modulate a biological activity expressed by a cell
SG11202000014UA (en) 2017-07-06 2020-01-30 Merus Nv Binding molecules that modulate a biological activity expressed by a cell
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
JP2020530028A (en) 2017-08-09 2020-10-15 メルス ナムローゼ フェンノートシャップ Antibodies that bind to EGFR and cMET
JP2021504413A (en) 2017-12-01 2021-02-15 メルス ナムローゼ フェンノートシャップ Use of bispecific antibody and IL-15 for combination therapy
SG11202003044SA (en) * 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
TWI804572B (en) 2018-02-09 2023-06-11 日商小野藥品工業股份有限公司 Bispecific antibody
KR20200135397A (en) 2018-03-24 2020-12-02 리제너론 파마슈티칼스 인코포레이티드 Genetically modified non-human animals for producing therapeutic antibodies against peptide-MHC complexes, methods of making the same
KR20200139189A (en) 2018-03-30 2020-12-11 메뤼스 엔.페. Polyvalent antibody
CN108624622A (en) * 2018-05-16 2018-10-09 湖南艾佳生物科技股份有限公司 A kind of genetically engineered cell strain that can secrete mouse interleukin -6 based on CRISPR-Cas9 systems structure
WO2019236671A1 (en) * 2018-06-08 2019-12-12 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain ii
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of engineered dh-dh rearrangement and uses thereof
EP3898685A1 (en) 2018-12-20 2021-10-27 Merus N.V. Clec12axcd3 bispecific antibodies and methods for the treatment of disease
WO2020132557A1 (en) 2018-12-21 2020-06-25 Compass Therapeutics Llc Transgenic mouse expressing common human light chain
CN113439089A (en) 2018-12-31 2021-09-24 美勒斯公司 truncated multivalent multivariate
EP3906255A1 (en) * 2018-12-31 2021-11-10 Merus N.V. Mixed binding domains
PE20212305A1 (en) 2019-01-22 2021-12-10 Bristol Myers Squibb Co ANTIBODIES AGAINST IL-7R ALPHA SUBUNIT AND USES OF THESE
EP3924384A1 (en) 2019-02-14 2021-12-22 Merus N.V. Combinations of binding moieties that bind egfr, her2 and her3
MA54943A (en) 2019-02-14 2021-12-22 Merus Nv PRODUCTION OF COMPOSITIONS COMPRISING TWO OR MORE ANTIBODIES
WO2020169022A1 (en) 2019-02-18 2020-08-27 Beijing Biocytogen Co., Ltd Genetically modified non-human animals with humanized immunoglobulin locus
TW202039578A (en) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3 binding molecules
TWI862565B (en) 2019-04-04 2024-11-21 日商小野藥品工業股份有限公司 Bispecific antibody
PH12021552833A1 (en) 2019-05-09 2023-01-16 Merus Nv Variant domains for multimerizing proteins and separation thereof
CN114502725A (en) * 2019-07-01 2022-05-13 特里安尼公司 Transgenic mammals and methods of use
KR20220030956A (en) * 2019-07-05 2022-03-11 오노 야꾸힝 고교 가부시키가이샤 Hematological cancer treatment by PD-1/CD3 bispecific protein
CA3149309A1 (en) * 2019-07-30 2021-02-04 Ono Pharmaceutical Co., Ltd. Bispecific antibody
EP3772518A1 (en) 2019-08-07 2021-02-10 Merus N.V. Modified human variable domains
MX2022002096A (en) 2019-08-19 2022-03-17 Merus Nv Treatment of cancer with a combination of an antibody that binds lgr5 and egfr and a topoisomerase i inhibitor.
GB201912008D0 (en) 2019-08-21 2019-10-02 Cambridge Entpr Ltd Antibody
JP2023504172A (en) 2019-12-02 2023-02-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Peptide-MHC II protein constructs and their uses
CN115038497A (en) 2019-12-24 2022-09-09 美勒斯公司 TGF-beta-RII binding proteins
CN114945596A (en) 2020-01-29 2022-08-26 美勒斯公司 Means and methods for modulating immune cell engagement effects
JP2023523006A (en) 2020-04-24 2023-06-01 メルス ナムローゼ フェンノートシャップ Cancer treatment with antibodies that bind to LGR5 and EGFR
EP4158034A4 (en) * 2020-06-02 2024-07-03 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMALS HAVING A LIGHT-CHAIN IMMUNOGLOBULIN LOCUS
EP4211155A1 (en) 2020-09-11 2023-07-19 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
JP2022060182A (en) * 2020-10-02 2022-04-14 小野薬品工業株式会社 Pharmaceutical composition comprising bispecific antibody as an active ingredient
MX2023006983A (en) 2020-12-15 2023-06-26 Merus Nv Treatment of cancers with an antibody that binds lgr5 and egfr.
AU2021398976A1 (en) 2020-12-16 2023-07-06 Merus N.V. Multispecific antibodies for the treatment of cancer
AU2021400584A1 (en) 2020-12-16 2023-06-29 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
US20240058444A1 (en) 2020-12-18 2024-02-22 Merus N.V. Antibody composition
CA3165366A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
CN118055949A (en) 2021-10-06 2024-05-17 美勒斯公司 Treatment of cancers with high EGFR expression treated with antibodies that bind at least EGFR
CN119868536A (en) 2022-01-25 2025-04-25 美勒斯公司 Combination therapy for the treatment of cancer
CN120058955A (en) 2022-03-07 2025-05-30 美勒斯公司 Treatment with antibodies that bind EGFR and cMET
WO2023172133A1 (en) 2022-03-07 2023-09-14 Merus N.V. Combination therapy including antibodies that bind egfr and cmet
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
AU2023408531A1 (en) 2022-12-23 2025-07-17 Merus N.V. Combination treatment of cancers using an antibody that binds at least egfr and an immune checkpoint inhibitor
WO2024144401A1 (en) 2022-12-28 2024-07-04 Merus N.V. Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
WO2025105961A1 (en) 2023-11-17 2025-05-22 Merus N.V. COMBINATION THERAPY INCLUDING ANTIBODIES THAT BIND EGFR AND cMET.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4531078A (en) 1983-10-27 1985-07-23 Polaroid Corporation Control circuit for electronic flash
GB8909218D0 (en) 1989-04-22 1989-06-07 Medical Res Council Improvements in or relating to enhancers
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) * 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (en) * 1990-08-29 1997-09-15 Genpharm Int PRODUCTION AND USE OF NON-HUMAN TRANSGENT ANIMALS FOR THE PRODUCTION OF HETEROLOGUE ANTIBODIES
JPH08140528A (en) * 1993-12-03 1996-06-04 Genpharm Internatl Inc Transgenic nonhuman animal capable of producing heteroantibody
US5885827A (en) * 1996-01-23 1999-03-23 The Regents Of The Universtiy Of California Eukaryotic high rate mutagenesis system
ES2246069T3 (en) * 1997-05-02 2006-02-01 Genentech, Inc. PROCEDURE FOR THE PREPARATION OF MULTI-SPECIFIC ANTIBODIES THAT HAVE COMMON AND MULTIMERIC COMPONENTS.
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1999050657A1 (en) * 1998-03-30 1999-10-07 Research Development Foundation Corticotropin releasing factor receptor 1-deficient mice
US20020028488A1 (en) * 2000-06-19 2002-03-07 Sujay Singh Transgenic avian species for making human and chimeric antibodies
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN100448992C (en) * 2001-05-11 2009-01-07 麒麟医药株式会社 Human Artificial Chromosome Containing Human Antibody λ Light Chain Gene
ES2368733T3 (en) 2002-07-18 2011-11-21 Merus B.V. RECOMBINANT PRODUCTION OF MIXTURES OF ANTIBODIES.
EP1439234A1 (en) * 2003-01-08 2004-07-21 ARTEMIS Pharmaceuticals GmbH Targeted transgenesis using the rosa26 locus
EP2395016A3 (en) 2003-05-30 2012-12-19 Merus B.V. Design and use of paired variable regions of specific binding molecules
AU2005205412B2 (en) 2004-01-20 2011-08-11 Merus N.V. Mixtures of binding proteins
JP4487068B2 (en) * 2004-10-12 2010-06-23 国立大学法人 岡山大学 Method for producing mutant protein by controlling gene mutation function of cell
WO2006117699A2 (en) * 2005-04-29 2006-11-09 Innate Pharma Transgenic animals and methods of making recombinant antibodies
EP2003960B1 (en) * 2006-03-31 2015-06-10 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ES2377579T3 (en) 2006-06-02 2012-03-29 Regeneron Pharmaceuticals, Inc. High-affinity antibodies against the human IL-6 receptor
MEP11109A (en) 2006-10-02 2011-12-20 High affinity human antibodies to human il-4 receptor
NO347649B1 (en) 2006-12-14 2024-02-12 Regeneron Pharma Human antibody or antibody fragment that specifically binds human delta-like ligand 4 (hDII4), nucleic acid molecule that codes for such and vector and host-vector systems, as well as method for production, composition and use.
SI2147594T1 (en) * 2008-06-27 2014-02-28 Merus B.V. Antibody producing non-human mammals
RU2724663C2 (en) * 2010-02-08 2020-06-25 Ридженерон Фармасьютикалз, Инк. Mouse with common light chain

Also Published As

Publication number Publication date
SG10201914019YA (en) 2020-03-30
WO2009157771A3 (en) 2010-02-18
ES2445193T3 (en) 2014-02-28
DK2147594T3 (en) 2014-02-10
EP2556747A3 (en) 2016-08-03
CN112481300A (en) 2021-03-12
HUE057994T2 (en) 2022-06-28
ES2853226T3 (en) 2021-09-15
PT2147594E (en) 2014-02-17
EP3456190B1 (en) 2021-11-24
CA2729095C (en) 2018-12-04
PL3456190T3 (en) 2022-06-06
EP3456192A1 (en) 2019-03-20
KR20190025068A (en) 2019-03-08
KR20170066688A (en) 2017-06-14
KR20200057093A (en) 2020-05-25
EP2147594A1 (en) 2010-01-27
KR20140127914A (en) 2014-11-04
RU2015119670A (en) 2015-12-10
JP2022188085A (en) 2022-12-20
CN102123582B (en) 2015-09-30
PT3456190T (en) 2022-02-15
KR102306491B1 (en) 2021-09-29
EP2556747A2 (en) 2013-02-13
RU2020127564A (en) 2022-02-21
PL2147594T3 (en) 2014-04-30
CN105191863A (en) 2015-12-30
EP3456191A1 (en) 2019-03-20
HK1154463A1 (en) 2012-04-27
JP6824807B2 (en) 2021-02-03
KR20110029156A (en) 2011-03-22
EP3456190A1 (en) 2019-03-20
CY1114830T1 (en) 2016-12-14
JP2020191882A (en) 2020-12-03
KR102112655B1 (en) 2020-05-19
JP2015156871A (en) 2015-09-03
DK2556747T3 (en) 2021-02-15
JP2011525808A (en) 2011-09-29
KR101990228B1 (en) 2019-06-17
RU2559524C2 (en) 2015-08-10
CN102123582A (en) 2011-07-13
JP5749161B2 (en) 2015-07-15
EP2556747B1 (en) 2020-12-02
RU2731084C2 (en) 2020-08-28
HRP20140139T1 (en) 2014-03-14
LT3456190T (en) 2022-03-10
JP2017121256A (en) 2017-07-13
AU2009263082A1 (en) 2009-12-30
ZA201009312B (en) 2011-08-31
SI2147594T1 (en) 2014-02-28
JP7242611B2 (en) 2023-03-20
CY1125119T1 (en) 2023-06-09
MX2010014542A (en) 2011-04-05
AU2009263082C1 (en) 2018-11-01
JP7439201B2 (en) 2024-02-27
AU2009263082B9 (en) 2014-07-17
SI3456190T1 (en) 2022-06-30
DK3456190T3 (en) 2022-02-14
RU2011102962A (en) 2012-08-10
RS53146B (en) 2014-06-30
NZ590118A (en) 2012-10-26
PT2556747T (en) 2021-02-15
KR102261586B1 (en) 2021-06-08
RU2020127564A3 (en) 2022-02-21
EP3456193A1 (en) 2019-03-20
JP2024063038A (en) 2024-05-10
AU2009263082B2 (en) 2014-03-20
EP2147594B1 (en) 2013-11-13
HRP20220205T1 (en) 2022-05-27
WO2009157771A2 (en) 2009-12-30
ES2906344T3 (en) 2022-04-18
RS62925B1 (en) 2022-03-31
RU2015119670A3 (en) 2019-01-22
CA2729095A1 (en) 2009-12-30
CN105191863B (en) 2020-12-22
SG10201914027VA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
SG10201408500RA (en) Antibody producing non-human mammals
ES3015425T3 (en) Mouse models and therapeutic molecules
DK1391511T3 (en) Human artificial chromosome containing human antibody lambda light chain gene
JP2020191882A5 (en)
RU2008134517A (en) OBTAINING ANTIBODIES FROM ONE HEAVY CHAINS IN TRANSGENIC ANIMALS
MXPA06000562A (en) Humanized immunoglobulin loci.
NZ597481A (en) Animal models and therapeutic molecules
IL202302A (en) Methods @ for production @ cells @ germ @ non-human @ owners @ site @ ig @ passed @ inactivation L @ animals @ transgenic @ including them and monoclonal antibodies @ produced @ them
MX2011007660A (en) Non-human transgenic animals expressing humanised antibodies and use therof.
MX2021010556A (en) Non-human animals having an engineered immunoglobulin lambda light chain locus.
WO2004024871A3 (en) Antibodies and methods for generating genetically altered antibodies with high affinity
MX378943B (en) NON-HUMAN ANIMALS EXPRESSING pH-SENSITIVE IMMUNOGLOBULIN SEQUENCES.
GB0110029D0 (en) Transgenic animal
ATE363068T1 (en) PRODUCTION OF A MONOCLONAL ANTIBODY BY A TRANSGENIC SPECIES OF BIRD
GB2272440A (en) Transgenic non-human animals capable of producing heterologous antibodies
RU2012128856A (en) Mice that make antibodies that have only a heavy chain
NO20090424L (en) Human antibodies to ErbB2
HN2004000285A (en) ANTIBODIES DIRECTED TO c-MET
JP2009502203A5 (en)
CY1116226T1 (en) USE TOY RNA FOR PROGRAMMING BODY CELLS
ATE537254T1 (en) MUTANT TRANSPOSON VECTOR AND USE THEREOF
ZA202213503B (en) Genetically modified non-human animals with common light chain immunoglobulin locus
ATE513852T1 (en) METHOD USING A TRANSGENIC ANIMAL WITH ENHANCED IMMUNE RESPONSE
ATE464389T1 (en) TRANSGENIC UNFOUND ANIMALS CAPABILITY OF PRODUCING HUMAN ANTIBODIES
AR043405A1 (en) SPECIFIC HUMAN ANTIBODIES FOR INTERLEUQUINE 15 (IL-15)